8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-09-16 AccNo: 0001213900-26-100350 Size: 218 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.
Allarity Therapeutics Announces SPAC Allarity Acquisition Corp. Filed Form S-1 For $100M IPO, Up To $115M With Over-Allotment; Sponsor Subsidiary To Own About 25%
Alvotech shares are trading higher after Barclays upgraded the stock from Underweight to Overweight rating and raised its price target from $4 to $8.
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.